RestructuringApr 29, 2026, 05:32 PM
AUTL Cuts 13% Workforce; $8M Restructuring Charge; Reaffirms 2026 Revenue
AI Summary
Autolus Therapeutics plc announced a strategic initiative to improve operational efficiency and reduce operating expenses, including a workforce reduction of approximately 13%. The company expects to incur total restructuring charges of approximately $8 million, primarily for severance and related costs, with the majority recognized in the first half of 2026. These actions are projected to reduce operating expenses by approximately $15 million on an annualized basis starting in 2027. Autolus reiterated its full-year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million and confirmed its cash runway into the fourth quarter of 2027.
Key Highlights
- Autolus Therapeutics announced a workforce reduction of approximately 13%.
- The company expects to incur total restructuring charges of approximately $8 million.
- Anticipated annualized operating expense reductions of approximately $15 million starting in 2027.
- Reiterated full-year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million.
- Confirmed cash, cash equivalents, and marketable securities sufficient to fund operations into Q4 2027.
- The plan's implementation is expected to be substantially complete by Q3 2026.
- 2025 AUCATZYL net product revenue was $74 million.
Price Impact
More from AUTL